| |
Thursday, April 6, 2023 | 11am ET / 8am PT In this webinar, we show how we used Nunchuck to make LNPs in small-volume screening runs and bulk formulations. The complete workflow will be illustrated, from the testing of flow rates in initial formulations to the final assessment of mRNA expression in multiple cell types, showing successful transfection of cells by the LNPs. Register now.
|
|
Today's Big NewsMar 31, 2023 |
|
April 3 - 4, 2023 | San Diego, CA Be a part of a learning experience developed by our esteemed Advisory Board who are leaders in the life science communications space. Time is running out! Register Today
|
|
| By Annalee Armstrong Eli Lilly’s up and coming Alzheimer’s disease treatment remternetug seems to have resulted in an early, dose-dependent reduction in amyloid plaques during a small phase 1 study. But the therapy also ran into a common side effect for the anti-amyloid monoclonal antibody class—although it is early days for the data. |
|
|
|
By Nick Paul Taylor Galapagos is taking a leaf out of the Sanofi playbook for offloading unwanted French R&D units. Seeking to slim down to execute its new strategy, the Belgian biotech has struck a deal to transfer a facility on the outskirts of Paris to the drug discovery contract research organization (CRO) NovAliX. |
By Max Bayer Cytokinetics' commercial ambitions met another late-stage stonewall, with the company’s amyotrophic lateral sclerosis (ALS) prospect coming up short when investigators took a look under the clinical hood. |
By James Waldron While biotech M&A may have cooled down over the past year, no one has told GreenLight Biosciences or Egitis Therapeutics, which are both mulling their own takeover offers. |
By Nick Paul Taylor Molecular Templates is fighting for survival. Facing threats that could sink the business, the Bristol Myers Squibb-partnered biotech is halving its 222-person team, stopping clinical development of a HER2 drug candidate and focusing its preclinical work on collaborations. |
By Gabrielle Masson Researchers have identified a new trigger for several mood disorders, potentially paving the way for new, faster-acting treatments. Glycine, a common amino acid and major neurotransmitter, has the ability to transport a “slow down” signal to the brain that likely plays a role in several mood disorders including major depressive order. |
By Conor Hale Dubbed the Epic Max, the valve is recommended for patients who need a replacement but shouldn’t take a regimen of blood thinners. |
By Nick Paul Taylor Drugmakers are failing to provide Europeans with the information to understand the benefits and harms of oncology medicines. That is the headline finding of a paper published in The BMJ, which found patient information leaflets routinely lack details that could support informed decision making. |
By Andrea Park Just a few weeks after a Kaiser Health News report uncovered a spate of complaints about the unregulated use of a dental device that patients say caused extensive damage, the FDA has begun looking into the issue. |
By Heather Landi Uber's healthcare arm rolled out same-day prescription delivery services, enabling clinicians to quickly ship medications to patients' homes. |
By Max Bayer,Gabrielle Masson After more than six months on the job market, Mathai Mammen, M.D., Ph.D., has found a new home, taking over as CEO of FogPharma. |
By Teresa Carey This week on "The Top Line," we discuss how 2023 is shaping up to be much the same as last year when it comes to financing trends for biotechs. We also cover Emergent's Narcan winning the first over-the-counter approval for an opioid-overdose drug and more of this week's top headlines. |
By Angus Liu Takeda is planning the company's biggest manufacturing expansion in Japan in its history. Eisai and Biogen's Leqembi could accumulate $12.9 billion sales through 2028, according to GlobalData. Three companies will make generics versions of GSK's long-acting HIV PrEP med in India. And more. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss how 2023 is shaping up to be much the same as last year when it comes to financing trends for biotechs. We also cover Emergent's Narcan winning the first over-the-counter approval for an opioid-overdose drug and more of this week's top headlines. |
|
|---|
|
|
|
May 1 - 3, 2023 | Jersey City, NJ Connect with senior executives in Medical Affairs, MSL and IIT to share best practices. Register Today & save $200 from now until April 7th!
|
|
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperThis paper describes the key elements of good US/EU corporate governance for US-based biopharma companies in operating Europe. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Executive SummaryRead about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines. Sponsored by: Twist Bioscience |
| WhitepaperHave you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
| Whitepaper Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success. Sponsored by: Herspiegel Consulting |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
